European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
Evolution, control and success of combination therapy with Ampicilin-sulbactam/Ceftazidime-Avibactam during a Carbapenem-Resistant Acinetobacter baumannii outbreak in burn Intensive Care Unit.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dudoignon Emmanuel, Caméléna Francois, Lafaurie Matthieu, Deniau Benjamin, Chaussard Maité, Coutrot Maxime, Guillemet Lucie, Cupaciu Alexandru, Pharaboz Alexandre, Boutin Louis, Benyamina Mourad, Chaouat Marc, Mimoun Maurice, Merimèche Manel, Mebazaa Alexandre, Plaud Benoit, Berçot Béatrice, Dépret François, Mellon Guillaume
Аннотация
We present our findings on interpatient transmission, epidemic control measures, and the outcomes of a series of ten critically ill burn patients who were either colonized or infected with carbapenem-resistant Acinetobacter baumannii (CRAB). None of the five infected patients achieved clinical cure, and all experienced relapses. Microbiological failure was observed in 40% of the infected patients. The isolated CRAB strains were found to carry blaOXA-23 and armA resistance genes. Despite the lack of clinical cure, all five infected patients survived and were discharged from the Burn Intensive Care Unit.
Предметные рубрики MeSH
Acinetobacter baumanniiHumansAcinetobacter InfectionsDisease OutbreaksAnti-Bacterial AgentsMaleAzabicyclo CompoundsIntensive Care UnitsSulbactamFemaleMiddle AgedDrug CombinationsAdultCarbapenemsCeftazidimeBurnsDrug Therapy, CombinationTreatment OutcomeAgedCross InfectionDrug Resistance, Multiple, Bacterialbeta-LactamasesBurn Units